Testosterone (T) is a medication and naturally occurring steroid hormone. It is used to treat male hypogonadism, gender dysphoria, and certain types of breast cancer. It may also be used to increase athletic ability in the form of doping. It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. Testosterone can be used as a gel or patch that is applied to the skin, injection into a muscle, tablet that is placed in the cheek, or tablet that is taken by mouth.
Common side effects of testosterone include acne, swelling, and breast enlargement in men. Serious side effects may include liver toxicity, heart disease, and behavioral changes. Women and children who are exposed may develop masculinization. It is recommended that individuals with prostate cancer not use the medication. It can cause harm to the baby if used during pregnancy or breastfeeding. Testosterone is in the androgen family of medications.
Testosterone was first isolated in 1935, and approved for medical use in 1939. Rates of use have increased three times in the United States between 2001 and 2011. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. It is available as a generic medication. The price depends on the dose and form of the product. In 2017, it was the 132nd most commonly prescribed medication in the United States, with more than five million prescriptions.
- 1 Medical uses
- 2 Non-medical use
- 3 Contraindications
- 4 Side effects
- 5 Interactions
- 6 Pharmacology
- 7 Chemistry
- 8 History
- 9 Society and culture
- 10 Research
- 11 References
- 12 Further reading
- 13 External links
The primary use of testosterone is the treatment of males with too little or no natural testosterone production, also termed hypogonadism or hypoandrogenism (androgen deficiency). This treatment is referred to as hormone replacement therapy (HRT), or alternatively, and more specifically, as testosterone replacement therapy (TRT) or androgen replacement therapy (ART). It is used to maintain serum testosterone levels in the normal male range. Decline of testosterone production with age has led to interest in testosterone supplementation.
A 2020 guidelines from the American College of Physicians support the discussion of testosterone in adult men with age-related low levels of testosterone who have sexual dysfunction. They recommend yearly evaluation regarding possible improvement and, if none, to discontinue testosterone; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar. Testosterone treatment for reasons other than possible improvement of sexual dysfunction may not be recommended.
Testosterone deficiency (also termed hypotestosteronism or hypotestosteronemia) is an abnormally low testosterone production. It may occur because of testicular dysfunction (primary hypogonadism) or hypothalamic–pituitary dysfunction (secondary hypogonadism) and may be congenital or acquired.[medical citation needed]
|Route||Medication||Major brand names||Form||Dosage|
|Oral||Testosteronea||–||Tablet||400–800 mg/day (in divided doses)|
|Testosterone undecanoate||Andriol, Jatenzo||Capsule||40–80 mg/2–4x day (with meals)|
|Methyltestosteroneb||Android, Metandren, Testred||Tablet||10–50 mg/day|
|Fluoxymesteroneb||Halotestin, Ora-Testryl, Ultandren||Tablet||5–20 mg/day|
|Buccal||Testosterone||Striant||Tablet||30 mg 2x/day|
|Methyltestosteroneb||Metandren, Oreton Methyl||Tablet||5–25 mg/day|
|Sublingual||Testosteroneb||Testoral||Tablet||5–10 mg 1–4x/day|
|Methyltestosteroneb||Metandren, Oreton Methyl||Tablet||10–30 mg/day|
|Intranasal||Testosterone||Natesto||Nasal spray||11 mg 3x/day|
|Transdermal||Testosterone||AndroGel, Testim, TestoGel||Gel||25–125 mg/day|
|Androderm, AndroPatch, TestoPatch||Non-scrotal patch||2.5–15 mg/day|
|Testoderm||Scrotal patch||4–6 mg/day|
|Axiron||Axillary solution||30–120 mg/day|
|Androstanolone (DHT)||Andractim||Gel||100–250 mg/day|
|Rectal||Testosterone||Rektandron, Testosteronb||Suppository||40 mg 2–3x/day|
|Injection (IM or SC)||Testosterone||Andronaq, Sterotate, Virosterone||Aqueous suspension||10–50 mg 2–3x/week|
|Testosterone propionateb||Testoviron||Oil solution||10–50 mg 2–3x/week|
|Testosterone enanthate||Delatestryl||Oil solution||50–250 mg 1x/1–4 weeks|
|Xyosted||Auto-injector||50–100 mg 1x/week|
|Testosterone cypionate||Depo-Testosterone||Oil solution||50–250 mg 1x/1–4 weeks|
|Testosterone isobutyrate||Agovirin Depot||Aqueous suspension||50–100 mg 1x/1–2 weeks|
|Testosterone phenylacetateb||Perandren, Androject||Oil solution||50–200 mg 1x/3–5 weeks|
|Mixed testosterone esters||Sustanon 100, Sustanon 250||Oil solution||50–250 mg 1x/2–4 weeks|
|Testosterone undecanoate||Aveed, Nebido||Oil solution||750–1,000 mg 1x/10–14 weeks|
|Testosterone buciclatea||–||Aqueous suspension||600–1,000 mg 1x/12–20 weeks|
|Implant||Testosterone||Testopel||Pellet||150–1,200 mg/3–6 months|
|Notes: Men produce about 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = Never marketed. b = No longer used and/or no longer marketed. Sources: See template.|
Low levels due to aging
Testosterone levels may decline gradually with age. The United States Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone supplement have been established for low testosterone levels due to aging. The FDA has required that labels on testosterone include warnings about increased risk of heart attacks and stroke.
To take advantage of its virilizing effects, testosterone is administered to transgender men and other transmasculine individuals as part of masculinizing hormone therapy, titrated to clinical effect with a "target level" of the average male's testosterone level.
|Testosterone undecanoate||Andriol, Jatenzo||Androgen||Oral||40–80 mg/2–3x day (with meals)|
|Testosterone||Striant||Androgen||Buccal||30 mg 2x/day|
|Natesto||Nasal spray||11 mg 3x/day|
|AndroGel, others||Transdermal gel||25–100 mg/day|
|Androderm, others||Transdermal patch||2.5–10 mg/day|
|Axiron||Axillary solution||30–120 mg/day|
|Testopel||Subcutaneous implant||150–600 mg/3–6 months|
|Testosterone enanthate||Delatestryl, others||Androgen||Injection (IM or SC)||50–100 mg/week or 100–250 mg/2–4 weeks|
|Testosterone cypionate||Depo-Testosterone, others||Androgen||Injection (IM or SC)||50–100 mg/week or 100–250 mg/2–4 weeks|
|Testosterone isobutyrate||Agovirin Depot||Androgen||Injection (IM or SC)||50–100 mg/week|
|Mixed testosterone esters||Sustanon 250, others||Androgen||Injection (IM or SC)||250 mg/2–3 weeks or 500 mg/3–6 weeks|
|Testosterone undecanoate||Aveed, Nebido, others||Androgen||Injection (IM or SC)||750–1,000 mg/10–14 weeks|
|GnRH analogue||Various||GnRH modulator||Parenteral (various)||Variable|
|Elagolix||Orilissa||GnRH antagonist||Oral||150 mg/day or 200 mg/twice a day|
|Medroxyprogesterone acetatea||Provera, others||Progestin||Oral||5–10 mg/day|
|Depo-Provera, others||Injection (IM)||150 mg/3 months|
|Depo-SubQ Provera 104||Injection (SC)||104 mg/3 months|
|Lynestrenola||Orgametril, others||Progestin||Oral||5–10 mg/day|
|Finasterideb||Propecia, Proscar||5α-Reductase inhibitor||Oral||1 mg/day|
|Dutasterideb||Avodart||5α-Reductase inhibitor||Oral||0.5 mg/day|
|Notes: Testes produce 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = For suppression of menses. b = For prevention/treatment of scalp hair loss. Sources: See template.|
Testosterone therapy is effective in the short-term for the treatment of hypoactive sexual desire disorder (HSDD) in women. However, its long-term safety is unclear. Because of a lack data to support its efficacy and safety, the Endocrine Society recommends against the routine use of testosterone in women to treat low androgen levels due to hypopituitarism, adrenal insufficiency, surgical removal of the ovaries, high-dose corticosteroid therapy, or other causes. Similarly, because of a lack of data to support its efficacy and safety, the Endocrine Society recommends against the use of testosterone in women to improve general well-being, to treat infertility, sexual dysfunction due to causes other than HSDD, or to improve cognitive, cardiovascular, metabolic, and/or bone health.
A 2014 systematic review and meta-analysis of 35 studies consisting of over 5,000 postmenopausal women with normal adrenal gland function found that testosterone therapy was associated with significant improvement in a variety of domains of sexual function. These domains included frequency of sexual activity, orgasm, arousal, and sexual satisfaction, among others. Women who were menopausal due to ovariectomy showed significantly greater improvement in sexual function with testosterone relative to those who had normal menopause. In addition to beneficial effects on sexual function, testosterone was associated with unfavorable changes in blood lipids. These included decreased levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol, and increased levels of low-density lipoprotein (LDL) cholesterol. However, the changes were small in magnitude, and the long-term significance in relation to cardiovascular outcomes is uncertain. The changes were more pronounced with oral testosterone undecanoate than with parenteral routes, such as transdermal testosterone. Testosterone showed no significant effect on depressed mood anxiety, bone mineral density (BMD), or anthropomorphic measures like body weight or body mass index. Conversely, it was associated with a significant incidence of androgenic side effects, including acne and hirsutism (excessive facial/body hair growth). Other androgenic side effects, such as weight gain, pattern hair loss, and voice deepening, were also reported in some trials, but were excluded from analyses due to insufficient data. The overall quality of the evidence was rated as low and was considered to be inconclusive in certain areas, for instance on long-term safety.
A subsequent 2017 systematic review and meta-analysis of studies including over 3,000 postmenopausal women with HSDD similarly found that short-term transdermal testosterone therapy was effective in improving multiple domains of sexual function. Androgenic adverse effects such as acne and hirsutism were significantly greater in incidence with testosterone therapy, whereas no significant differences in "increase in facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction to the patch, total adverse events, serious adverse events, reasons for withdrawal from the study, and the number of women who completed the study" were seen relative to controls.
Although testosterone has been found to be effective at improving sexual function in postmenopausal women, the doses employed have been supraphysiological. In contrast to these high doses, there is little support for the notion that testosterone is a critical hormone for sexual desire and function in women under normal physiological circumstances. Low doses of testosterone resulting in physiological levels of testosterone (<50 ng/dL) have not been found to significantly increase sexual desire or function in women in most studies. Similarly, there appears to be little or no relationship between total or free testosterone levels in the normal physiological range and sexual desire in premenopausal women. Only high doses of testosterone resulting in supraphysiological levels of testosterone (>50 ng/dL) significantly increase sexual desire in women, with levels of testosterone of 80 to 150 ng/dL "slightly" increasing sex drive. In accordance, men experience sexual dysfunction at testosterone levels of below 300 ng/dL, and men that have levels of testosterone of approximately 200 ng/dL frequently experience such problems. The high doses of testosterone required to increase sexual desire in women may have a significant risk of masculinization with long-term therapy. For this reason, and due to the unknown health effects and safety of testosterone therapy, its use may be inappropriate. In 2003, the FDA rejected Intrinsa, a 300 µg/day testosterone patch for the treatment of sexual dysfunction in postmenopausal women. The reasons cited were limited efficacy (about one additional sexually satisfying event per month), concerns about safety and potential adverse effects with long-term therapy, and concerns about inappropriate off-label use. It appears that in women, rather than testosterone, estradiol may be the most important hormone involved in sexual desire, although data on the clinical use of estradiol to increase sexual desire in women is limited.
There are no testosterone products approved for use in women in the United States and many other countries. There are approved testosterone products for women in Australia and some European countries. Testosterone pellet implants are approved for use in postmenopausal women in the United Kingdom. Testosterone products for men can be used off-label in women in the United States. Alternatively, testosterone products for women are available from compounding pharmacies in the United States, although such products are unregulated and manufacturing quality is not ensured.
|Route||Medication||Major brand names||Form||Dosage|
|Oral||Testosterone undecanoate||Andriol, Jatenzo||Capsule||40–80 mg 1x/1–2 days|
|Methyltestosterone||Metandren, Estratest||Tablet||0.5–10 mg/day|
|Fluoxymesterone||Halotestin||Tablet||1–2.5 mg 1x/1–2 days|
|Prasterone (DHEA)b||–||Tablet||10–100 mg/day|
|AndroGel||Gel, cream||1–10 mg/day|
|Vaginal||Prasterone (DHEA)||Intrarosa||Insert||6.5 mg/day|
|Injection||Testosterone propionatea||Testoviron||Oil solution||25 mg 1x/1–2 weeks|
|Testosterone enanthate||Delatestryl, Primodian Depot||Oil solution||25–100 mg 1x/4–6 weeks|
|Testosterone cypionate||Depo-Testosterone, Depo-Testadiol||Oil solution||25–100 mg 1x/4–6 weeks|
|Testosterone isobutyratea||Femandren M, Folivirin||Aqueous suspension||25–50 mg 1x/4–6 weeks|
|Mixed testosterone esters||Climacterona||Oil solution||150 mg 1x/4–8 weeks|
|Omnadren, Sustanon||Oil solution||50–100 mg 1x/4–6 weeks|
|Nandrolone decanoate||Deca-Durabolin||Oil solution||25–50 mg 1x/6–12 weeks|
|Prasterone enanthatea||Gynodian Depot||Oil solution||200 mg 1x/4–6 weeks|
|Implant||Testosterone||Testopel||Pellet||50–100 mg 1x/3–6 months|
|Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.|
|Fluoxymesterone||Tablet||10–40 mg 3x/day|
|Calusterone||Tablet||40–80 mg 4x/day|
|Injection (IM or SC)||Testosterone propionate||Oil solution||50–100 mg 3x/week|
|Testosterone enanthate||Oil solution||200–400 mg 1x/2–4 weeks|
|Testosterone cypionate||Oil solution||200–400 mg 1x/2–4 weeks|
|Mixed testosterone esters||Oil solution||250 mg 1x/week|
|Methandriol||Aqueous suspension||100 mg 3x/week|
|Androstanolone (DHT)||Aqueous suspension||300 mg 3x/week|
|Drostanolone propionate||Oil solution||100 mg 1–3x/week|
|Metenolone enanthate||Oil solution||400 mg 3x/week|
|Nandrolone decanoate||Oil solution||50–100 mg 1x/1–3 weeks|
|Nandrolone phenylpropionate||Oil solution||50–100 mg/week|
|Note: Dosages are not necessarily equivalent. Sources: See template.|
Testosterone has been marketed for use by oral, sublingual, buccal, intranasal, transdermal (patches), topical (gels), intramuscular (injection), and subcutaneous (implant administration. It is provided unmodified and as a testosterone ester such as testosterone cypionate, testosterone enanthate, testosterone propionate, or testosterone undecanoate, which act as prodrugs of testosterone. The most common route of administration for testosterone is by intramuscular injection. However, it has been reported that AndroGel, a transdermal gel formulation of testosterone, has become the most popular form of testosterone in androgen replacement therapy for hypogonadism in the United States.
|Route||Ingredient||Form||Dose||Frequency||Major brand names|
|Oral||Testosterone undecanoate||Capsule||40 mg||2–4x per day||Andriol, Andriol Testocaps, Jatenzo|
|Sublingual||Testosterone||Tablet||10 mg||1–4x per day||Testoral|
|Buccal||Testosterone||Tablet||30 mg||2x per day||Striant|
|Intranasal||Testosterone||Nasal gel||5.5 mg per spray (120 sprays per bottle)||3x per day||Natesto|
|Transdermal||Testosterone||Non-scrotal patch||2.5, 4, 5, or 6 mg T per day||1x every 1–2 days||Androderm, AndroPatch, TestoPatch|
|Non-scrotal patch||150 or 300 μg T per day||1x every 3–4 days||Intrinsa|
|Scrotal patch||4 or 6 mg T per day||1x per day||Testoderm|
|Topical gel (1–2.5%)||25, 50, 75, 100, or 125 mg T per application||1x per day||AndroGel, Testim, TestoGel|
|Axillary solution (2%)||30 mg T per application||1x per day||Axiron|
|Rectal||Testosterone||Suppository||40 mg||2–3x per day||Rektandron, Testosteron|
|Injection (IM or SC)||Testosteronea||Aqueous suspension||25, 50, or 100 mg/mL||1x every 2–3 days||Andronaq, Sterotate, Virosterone|
|Testosterone propionatea||Oil solution||5, 10, 25, 50, or 100 mg/mL||1x every 2–3 days||Testoviron|
|Testosterone isobutyratea||Aqueous suspension||25 mg/mL||1x every 1–2 weeks||Agovirin-Depot, Perandren M|
|Testosterone enanthate||Oil solution||50, 100, 180, 200, or 250 mg/mL||1x every 1–4 weeks||Delatestryl|
|Testosterone cypionate||Oil solution||50, 100, 200, or 250 mg/mL||1x every 1–4 weeks||Depo-Testosterone|
|Mixed testosterone esters||Oil solution||100 or 250 mg/mL||1x every 2–4 weeks||Sustanon 100, Sustanon 250|
|Testosterone undecanoate||Oil solution||750 or 1000 mg per injection||1x every 10–14 weeks||Aveed, Nebido, Reandron|
|Implant||Testosterone||Pellet||50, 75, 100, or 200 mg||1x every 3–6 months||TestoImplant, Testopel|
|Abbreviations: T = Testosterone. Footnotes: a = Discontinued or mostly discontinued. Notes: (1): This table does not include dosage information, which cannot necessarily be extrapolated from the provided information. (2): This table mostly does not include combination products. (3): Some of these formulations have been marketed previously but may no longer be available (e.g., transdermal testosterone scrotal patches, intramuscular testosterone suspension, intramuscular testosterone propionate). (4): The availability of pharmaceutical testosterone products differs by country (see Testosterone (medication) § Availability). Sources: See template.|
Testosterone is used as a form of doping among athletes in order to improve performance. Testosterone is classified as an anabolic agent and is on the World Anti-Doping Agency (WADA) List of Prohibited Substances and Methods. Hormone supplements cause the endocrine system to adjust its production and lower the natural production of the hormone, so when supplements are discontinued, natural hormone production is lower than it was originally.
Anabolic–androgenic steroids (AAS), including testosterone and its esters, have also been taken to enhance muscle development, strength, or endurance. They do so directly by increasing the muscles' protein synthesis. As a result, muscle fibers become larger and repair faster than the average person's.
After a series of scandals and publicity in the 1980s (such as Ben Johnson's improved performance at the 1988 Summer Olympics), prohibitions of AAS use were renewed or strengthened by many sports organizations. Testosterone and other AAS were designated a "controlled substance" by the United States Congress in 1990, with the Anabolic Steroid Control Act. Their use is seen as an issue in modern sport, particularly given the lengths to which athletes and professional laboratories go to in trying to conceal such use from sports regulators. Steroid use once again came into the spotlight as a result of Canadian professional wrestler Chris Benoit's double murder-suicide in 2007; however, there is no evidence implicating steroid use as a factor in the incident.
Some female athletes may have naturally higher levels of testosterone than others, and may be asked to consent to sex verification and either surgery or drugs to decrease testosterone levels. This has proven contentious, with the Court of Arbitration for Sport suspending the IAAF policy due to insufficient evidence of a link between high androgen levels and improved athletic performance.
Detection of abuse
A number of methods for detecting testosterone use by athletes have been employed, most based on a urine test. These include the testosterone/epitestosterone ratio (normally less than 6), the testosterone/luteinizing hormone ratio and the carbon-13/carbon-12 ratio (pharmaceutical testosterone contains less carbon-13 than endogenous testosterone). In some testing programs, an individual's own historical results may serve as a reference interval for interpretation of a suspicious finding. Another approach being investigated is the detection of the administered form of testosterone, usually an ester, in hair.
Absolute contraindications of testosterone include prostate cancer, elevated hematocrit (>54%), uncontrolled congestive heart failure, various other cardiovascular diseases, and uncontrolled obstructive sleep apnea. Breast cancer is said by some sources to be an absolute contraindication of testosterone therapy, but androgens including testosterone have also actually been used to treat breast cancer. Relative contraindications of testosterone include elevated prostate-specific antigen (PSA) in men with a high risk of prostate cancer due to ethnicity or family history, severe lower urinary tract symptoms, and elevated hematocrit (>50%).
Adverse effects may also include minor side effects such as oily skin, acne, and seborrhea, as well as loss of scalp hair, which may be prevented or reduced with 5α-reductase inhibitors. In women, testosterone can produce hirsutism (excessive facial/body hair growth), deepening of the voice, and other signs of virilization. Exogenous testosterone may cause suppression of spermatogenesis in men, leading to, in some cases, reversible infertility. Gynecomastia and breast tenderness may occur with high dosages of testosterone due to peripheral conversion of testosterone by aromatase into excessive amounts of the estrogen estradiol. Testosterone treatment, particularly in high dosages, can also be associated with mood changes, increased aggression, increased sex drive, spontaneous erections, and nocturnal emissions.
The FDA stated in 2015 that neither the benefits nor the safety of testosterone have been established for low testosterone levels due to aging. The FDA has required that testosterone pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke. They have also required the label include concerns about abuse and dependence.
Long-term adverse effects
Adverse effects of testosterone supplementation may include increased cardiovascular events (including strokes and heart attacks) and deaths based on three peer-reviewed studies involving men taking testosterone replacement. In addition, an increase of 30% in deaths and heart attacks in older men has been reported. Due to an increased incidence of adverse cardiovascular events compared to a placebo group, a Testosterone in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee. On January 31, 2014, reports of strokes, heart attacks, and deaths in men taking FDA-approved testosterone-replacement led the FDA to announce that it would be investigating the issue. Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT). The FDA now requires warnings in the drug labeling of all approved testosterone products regarding deep vein thrombosis and pulmonary embolism.
Up to the year 2010, studies had not shown any effect on the risk of death, prostate cancer or cardiovascular disease; more recent[when?] studies, however, do raise concerns. A 2013 study, published in the Journal of the American Medical Association, reported "the use of testosterone therapy was significantly associated with increased risk of adverse outcomes." The study began after a previous, randomized, clinical trial of testosterone therapy in men was stopped prematurely "due to adverse cardiovascular events raising concerns about testosterone therapy safety."
Testosterone in the presence of a slow-growing prostate cancer is assumed to increase its growth rate. However, the association between testosterone supplementation and the development of prostate cancer is unproven. Nevertheless, physicians are cautioned about the cancer risk associated with testosterone supplementation.
It may accelerate pre-existing prostate cancer growth in individuals who have undergone androgen deprivation. It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy.
Ethnic groups have different rates of prostate cancer. Differences in sex hormones, including testosterone, have been suggested as an explanation for these differences. This apparent paradox can be resolved by noting that prostate cancer is very common. In autopsies, 80% of 80-year-old men have prostate cancer.
Pregnancy and breastfeeding
Testosterone is contraindicated in pregnancy and not recommended during breastfeeding. Androgens like testosterone are teratogens and are known to cause fetal harm, such as producing virilization and ambiguous genitalia.
5α-Reductase inhibitors like finasteride and dutasteride can slightly increase circulating levels of testosterone by inhibiting its metabolism. However, these drugs do this via prevention of the conversion of testosterone into its more potent metabolite dihydrotestosterone (DHT), and this results in dramatically reduced circulating levels of DHT (which circulates at much lower relative concentrations). In addition, local levels of DHT in so-called androgenic (5α-reductase-expressing) tissues are also markedly reduced, and this can have a strong impact on certain effects of testosterone. For instance, growth of body and facial hair and penile growth induced by testosterone may be inhibited by 5α-reductase inhibitors, and this could be considered undesirable in the context of, for instance, puberty induction. On the other hand, 5α-reductase inhibitors may prevent or reduce adverse androgenic side effects of testosterone like scalp hair loss, oily skin, acne, and seborrhea. In addition to the prevention of testosterone conversion into DHT, 5α-reductase inhibitors also prevent the formation of neurosteroids like 3α-androstanediol from testosterone, and this may have neuropsychiatric consequences in some men.
Aromatase inhibitors like anastrozole prevent the conversion of testosterone into estradiol by aromatase. As only a very small fraction of testosterone is converted into estradiol, this does not affect testosterone levels, but it can prevent estrogenic side effects like gynecomastia that can occur when testosterone is administered at relatively high dosages. However, estradiol exerts negative feedback on the hypothalamic–pituitary–gonadal axis and, for this reason, prevention of its formation can reduce this feedback and disinhibit gonadal production of testosterone, which in turn can increase levels of endogenous testosterone. Testosterone therapy is sometimes combined with an aromatase inhibitor for men with secondary hypogonadism who wish to conceive children with their partners.
Cytochrome P450 inhibitors
Antiandrogens and estrogens
Antiandrogens like cyproterone acetate, spironolactone, and bicalutamide can block the androgenic and anabolic effects of testosterone. Estrogens can reduce the effects of testosterone by increasing the hepatic production and in turn circulating levels of sex hormone-binding globulin (SHBG), a carrier protein that binds to and occupies androgens like testosterone and DHT, and thereby reducing free concentrations of these androgens.
|Notes: In rodents. Footnotes: a = Ratio of androgenic to anabolic activity. Sources: See template.|
Testosterone is a high affinity ligand for and agonist of the nuclear androgen receptor (AR). In addition, testosterone binds to and activates membrane androgen receptors (mARs) such as GPRC6A and ZIP9. Testosterone is also potentiated via transformation by 5α-reductase into the more potent androgen DHT in so-called androgenic tissues such as the prostate gland, seminal vesicles, skin, and hair follicles. In contrast to the case of testosterone, such potentiation occurs to a reduced extent or not at all with most synthetic AAS (as well as with DHT), and this is primarily responsible for the dissociation of anabolic and androgenic effects with these agents. In addition to DHT, testosterone is converted at a rate of approximately 0.3% into the estrogen estradiol via aromatase. This occurs in many tissues, especially adipose tissue, the liver, and the brain, but primarily in adipose tissue. Testosterone, after conversion into DHT, is also metabolized into 3α-androstanediol, a neurosteroid and potent positive allosteric modulator of the GABAA receptor, and 3β-androstanediol, a potent and preferential agonist of the ERβ. These metabolites, along with estradiol, may be involved in a number of the effects of testosterone in the brain, including its antidepressant, anxiolytic, stress-relieving, rewarding, and pro-sexual effects.
Effects in the body and brain
The ARs are expressed widely throughout the body, including in the penis, testicles, epididymides, prostate gland, seminal vesicles, fat, skin, bone, bone marrow, muscle, larynx, heart, liver, kidneys, pituitary gland, hypothalamus, and elsewhere throughout the brain. Through activation of the ARs (as well as the mARs), testosterone has many effects, including the following:[additional citation(s) needed]
- Promotes growth, function, and maintenance of the prostate gland, seminal vesicles, and penis during puberty and thereafter
- Promotes growth and maintenance of muscles, particularly of the upper body
- Causes subcutaneous fat to be deposited in a masculine pattern and decreases overall body fat
- Suppresses breast development induced by estrogens, but can also still produce gynecomastia via excessive conversion into estradiol if levels are too high
- Maintains skin health, integrity, appearance, and hydration and slows the rate of aging of the skin, but can also cause oily skin, acne, and seborrhea
- Promotes the growth of facial and body hair, but can also cause scalp hair loss and hirsutism
- Contributes to bone growth and causes broadening of the shoulders at puberty
- Modulates liver protein synthesis, such as the production of sex hormone-binding globulin and many other proteins
- Increases production of erythropoietin in the kidneys and thereby stimulates red blood cell production in bone marrow and elevates hematocrit
- Exerts negative feedback on the hypothalamic–pituitary–gonadal axis by suppressing the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, thereby inhibiting gonadal sex hormone production as well as spermatogenesis and fertility
- Regulates the vasomotor system and body temperature via the hypothalamus, thereby preventing hot flashes
- Modulates brain function, with effects on mood, emotionality, aggression, and sexuality, as well as cognition and memory
- Increases sex drive and erectile capacity and causes spontaneous erections and nocturnal emissions
- Increases the risk of benign prostatic hyperplasia and prostate cancer and accelerates the progression of prostate cancer
- Decreases breast proliferation and the risk of breast cancer
Testosterone can be taken by a variety of different routes of administration. These include oral, buccal, sublingual, intranasal, transdermal (gels, creams, patches), rectal suppositories), by intramuscular or subcutaneous injection (in oil or aqueous), and as a subcutaneous implant. The pharmacokinetics of testosterone, including its bioavailability, circulating testosterone levels, metabolism, biological half-life, and other parameters, differ by route of administration.
Testosterone is a naturally occurring androstane steroid and is also known by the chemical name androst-4-en-17β-ol-3-one. It has a double bond between the C4 and C5 positions (making it an androstene), a ketone group at the C3 position, and a hydroxyl (alcohol) group at the C17β position.
Testosterone esters are substituted at the C17β position with a lipophilic fatty acid ester moiety of varying chain length. Major testosterone esters include testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone undecanoate. A C17β ether prodrug of testosterone, cloxotestosterone acetate, has also been marketed, although it is little known and is used very rarely or no longer. Another C17β ether prodrug of testosterone, silandrone, also exists but was never marketed, and is notable in that it is orally active. In addition to ester and ether prodrugs, androgen prohormones or precursors of testosterone, such as dehydroepiandrosterone (DHEA), androstenediol, and androstenedione, exist as well, and convert into testosterone to variable extents upon oral ingestion. Unlike testosterone ester and ether prodrugs however, these prohormones are only weakly androgenic/anabolic.
All synthetic AAS are derivatives of testosterone. Prominent examples include nandrolone (19-nortestosterone), metandienone (17α-methyl-δ1-testosterone), and stanozolol (a 17α-alkylated derivative of DHT). Unlike testosterone, AAS that are 17α-alkylated, like metandienone and stanozolol, are orally active. This is due to steric hindrance of C17β-position metabolism during the first-pass through the liver. In contrast, most AAS that are not 17α-alkylated, like nandrolone, are not active orally, and must instead be administered via intramuscular injection. This is almost always in ester form; for instance, in the case of nandrolone, as nandrolone decanoate or nandrolone phenylpropionate.
|Testosterone propionate||C17β||Propanoic acid||Straight-chain fatty acid||3||1.19||0.84||10||Short|
|Testosterone isobutyrate||C17β||Isobutyric acid||Aromatic fatty acid||– (~3)||1.24||0.80||9||Moderate|
|Testosterone cypionate||C17β||Cyclopentylpropanoic acid||Aromatic fatty acid||– (~6)||1.43||0.70||8||Moderate|
|Testosterone phenylpropionate||C17β||Phenylpropanoic acid||Aromatic fatty acid||– (~6)||1.46||0.69||7||Moderate|
|Testosterone isocaproate||C17β||Isohexanoic acid||Branched-chain fatty acid||– (~5)||1.34||0.75||6||Moderate|
|Testosterone caproate||C17β||Hexanoic acid||Straight-chain fatty acid||6||1.35||0.75||5||Moderate|
|Testosterone enanthate||C17β||Heptanoic acid||Straight-chain fatty acid||7||1.39||0.72||4||Moderate|
|Testosterone decanoate||C17β||Decanoic acid||Straight-chain fatty acid||10||1.53||0.65||3||Long|
|Testosterone undecanoate||C17β||Undecanoic acid||Straight-chain fatty acid||11||1.58||0.63||2||Long|
|Testosterone buciclated||C17β||Bucyclic acide||Aromatic carboxylic acid||– (~9)||1.58||0.63||1||Long|
|Footnotes: a = Length of ester in carbon atoms for straight-chain fatty acids or approximate length of ester in carbon atoms for aromatic fatty acids. b = Relative testosterone content by weight (i.e., relative androgenic/anabolic potency). c = Duration by intramuscular or subcutaneous injection in oil solution (except TiB and TB, which are in aqueous suspension). d = Never marketed. e = Bucyclic acid = trans-4-Butylcyclohexane-1-carboxylic acid. Sources: See individual articles.|
Testosterone was first isolated and synthesized in 1935. Shortly thereafter, in 1937, testosterone first became commercially available as a pharmaceutical drug in the form of pellets and then in ester form for intramuscular injection as the relatively short-acting testosterone propionate. Methyltestosterone, one of the first synthetic AAS and orally active androgens, was introduced in 1935, but was associated with hepatotoxicity and eventually became largely medically obsolete. In the mid-1950s, the longer-acting testosterone esters testosterone enanthate and testosterone cypionate were introduced. They largely superseded testosterone propionate and became the major testosterone esters used medically for over half a century. In the 1970s, testosterone undecanoate was introduced for oral use in Europe, although intramuscular testosterone undecanoate had already been in use in China for several years. Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later (in the early to mid 2000s and 2014, respectively).
Society and culture
In the US in the 2000s, companies and figures in the popular media have heavily marketed notions of "andropause" as something parallel to menopause; these notions have been rejected by the medical community. Additionally, advertising from drug companies selling testosterone and human growth hormone, as well as dietary supplement companies selling all kinds of "boosters" for aging men, have emphasized the "need" of middle-aged or ageing men for testosterone. There is a medical condition called late-onset hypogonadism; according to Thomas Perls and David J. Handelsman, writing in a 2015 editorial in the Journal of the American Geriatrics Society, it appears that this condition is overdiagnosed and overtreated. Perls and Handelsman note that in the US, "sales of testosterone increased from $324 million in 2002 to $2 billion in 2012, and the number of testosterone doses prescribed climbed from 100 million in 2007 to half a billion in 2012, not including the additional contributions from compounding pharmacies, Internet, and direct-to-patient clinic sales."
Testosterone is the generic name of testosterone in English and Italian and the INN, USAN, USP, BAN, and DCIT of the drug, while testostérone is its French name and the DCF. It is also referred to in Latin as testosteronum, in Spanish and Portuguese as testosterona, and in German, Dutch, and Russian and other Slavic languages as testosteron. The Cyrillic script of testosterone is тестостерон.
Testosterone is marketed under a large number of brand names throughout the world. Major brand names of testosterone and/or its esters include Andriol, Androderm, AndroGel, Axiron, Delatestryl, Depo-Testosterone, Intrinsa, Nebido, Omnadren, Primoteston, Sustanon, Testim, TestoGel, TestoPatch, Testoviron, and Tostran.
- Topical gels: AndroGel, Fortesta, Testim, Testosterone (generic)
- Topical solutions: Axiron, Testosterone (generic)
- Transdermal patches: Androderm, Testoderm (discontinued), Testoderm TTS (discontinued), Testosterone (generic)
- Intranasal gels: Natesto
- Buccal tablets: Striant
- Pellet implants: Testopel
And the following ester prodrugs of testosterone are available in the United States in oil solutions for intramuscular injection:
- Testosterone cypionate: Depo-Testosterone, Testosterone Cypionate (generic)
- Testosterone enanthate: Delatestryl, Testosterone Enanthate (generic)
- Testosterone propionate: Testosterone Propionate (generic)
- Testosterone undecanoate: Aveed
Unmodified testosterone was also formerly available for intramuscular injection but was discontinued.
Testosterone cypionate and testosterone enanthate were formerly available in combination with estradiol cypionate and estradiol valerate, respectively, under the brand names Depo-Testadiol and Ditate-DS, respectively, as oil solutions for intramuscular injection, but these formulations have been discontinued.
As of November 2016[update], testosterone is available in Canada in the form of topical gels (AndroGel, Testim), topical solutions (Axiron), transdermal patches (Androderm), and intranasal gels (Natesto). Testosterone cypionate (Depo-Testosterone, Testosterone Cypionate (generic)), testosterone enanthate (Delatestryl, PMS-Testosterone Enanthate), and testosterone propionate (Testosterone Propionate (generic)) are available as oil solutions for intramuscular injection and testosterone undecanoate (Andriol, PMS-Testosterone, Taro-Testosterone) is available in the form of oral capsules. Testosterone buccal tablets and pellet implants do not appear to be available in Canada.
Testosterone and/or its esters are widely available in countries throughout the world in a variety of formulations.
Testosterone and its esters, along with other AAS, are prescription-only controlled substances in many countries throughout the world. In the United States, they are Schedule III drugs under the Controlled Substances Act, in Canada, they are Schedule IV drugs under the Controlled Drugs and Substances Act, and in the United Kingdom, they are Class C drugs under the Misuse of Drugs Act.
As of 2014[update], a number of lawsuits are underway against manufacturers of testosterone, alleging a significantly increased rate of stroke and heart attack in elderly men who use testosterone supplementation.[needs update]
Doping in sports
Testosterone has been used to treat depression in men who are of middle age with low testosterone. However, a 2014 review showed no benefit on the mood of the men with normal levels of testosterone or on the mood of the older men with low testosterone. Conversely, a 2009 review found that testosterone had an antidepressant effect in men with depression, especially those with hypogonadism, HIV/AIDS, and in the elderly.
Testosterone replacement can significantly improve exercise capacity, muscle strength and reduce QT intervals in men with chronic heart failure (CHF). Over the 3 to 6-month course of the studies reviewed, testosterone therapy appeared safe and generally effective, and (ruling out prostate cancer) the authors found no justification to absolutely restrict its use in men with CHF. A similar 2012 review also found increased exercise capacity and reasoned the benefits generlizable to women. However, both reviews advocate larger, longer term, randomized controlled trials.
Testosterone, as esters such as testosterone undecanoate or testosterone buciclate, has been studied and promoted as a male contraceptive analogous to estrogen-based contraceptives in women. Otherwise considered an adverse effect of testosterone, reduced spermatogenesis can be further suppressed with the addition of a progestin such as norethisterone enanthate or levonorgestrel butanoate, improving the contraceptive effect.
Scalp hair loss
A study found that of 76 pre- and postmenopausal women with hair thinning, 63% experienced hair regrowth when treated with subcutaneous testosterone implants that resulted in average testosterone levels of over 300 ng/dL for 12 months. No woman reported hair loss or thinning during testosterone treatment.
- Testosterone. Oxford Dictionaries.
- "Testosterone Use During Pregnancy". Drugs.com. August 20, 2019. Retrieved January 8, 2020.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved September 21, 2020.
- Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (November 11, 2015). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 709, 711, 765. ISBN 978-0-323-34157-8.
- "Testosterone". Drugs.com. American Society of Health-System Pharmacists. December 4, 2015. Archived from the original on August 20, 2016. Retrieved September 3, 2016.
- "List of Gender Dysphoria Medications (6 Compared)". Drugs.com. Retrieved May 6, 2020.
- Staff (March 3, 2015). "Testosterone Products: Drug Safety Communication – FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke". FDA. Archived from the original on March 5, 2015. Retrieved March 5, 2015.
- Taylor WN (2002). Anabolic Steroids and the Athlete (2 ed.). McFarland. p. 180. ISBN 978-0-7864-1128-3. Archived from the original on September 14, 2016.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 481. ISBN 9783527607495.
- Desroches B, Kohn TP, Welliver C, Pastuszak AW (April 2016). "Testosterone therapy in the new era of Food and Drug Administration oversight". Translational Andrology and Urology. 5 (2): 207–12. doi:10.21037/tau.2016.03.13. PMC 4837303. PMID 27141448.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 197. ISBN 978-1-284-05756-0.
- "The Top 300 of 2020". ClinCalc. Retrieved April 11, 2020.
- "Testosterone - Drug Usage Statistics". ClinCalc. Retrieved April 11, 2020.
- Winn, Katherine L. Margo|Robert (May 2006). "Testosterone Treatments: Why, When, and How?". American Family Physician. 73 (9): 1591–1598. Archived from the original on October 3, 2016. Retrieved October 3, 2016.
- Myers JB, Meacham RB (2003). "Androgen replacement therapy in the aging male". Reviews in Urology. 5 (4): 216–26. PMC 1508369. PMID 16985841.
- Qaseem A, Horwitch CA, Vijan S, Etxeandia-Ikobaltzeta I, Kansagara D (January 2020). "Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians". Annals of Internal Medicine. 172 (2): 126–133. doi:10.7326/M19-0882. PMID 31905405.
- Parry NM (January 7, 2020). "New Guideline for Testosterone Treatment in Men With 'Low T'". Medscape.com. Retrieved January 7, 2020.
- Gould DC, Petty R (August 2000). "The male menopause: does it exist?: for: some men need investigation and testosterone treatment". The Western Journal of Medicine. 173 (2): 76–8. doi:10.1136/ewjm.173.2.76. PMC 1070997. PMID 10924412.
- Liverman CT, Blazer DG, Institute of Medicine (US) Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy (January 1, 2004). "Introduction". Testosterone and Aging: Clinical Research Directions. National Academies Press (US). doi:10.17226/10852. ISBN 978-0-309-09063-6. PMID 25009850 – via www.ncbi.nlm.nih.gov.
- Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Jamrozik K, Flicker L (May 2007). "In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study". European Journal of Endocrinology. 156 (5): 585–94. doi:10.1530/EJE-06-0714. PMID 17468195.
- "Gender dysphoria – Treatment". NHS Gov.uk. May 21, 2012. Archived from the original on November 2, 2013. Retrieved October 31, 2013.
- Gorton RN, Buth J, Spade D. "Medical Therapy and Health Maintenance for Transgender Men: A Guide For Health Care Providers" (PDF). Lyon-Martin Women's Health Services. Archived (PDF) from the original on November 30, 2016. Retrieved December 11, 2016.
- Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N (October 2014). "Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism. 99 (10): 3489–510. doi:10.1210/jc.2014-2260. PMID 25279570.
- Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, Nabhan M, Firwana B, Altayar O, Prokop L, Montori VM, Murad MH (2014). "Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis". J. Clin. Endocrinol. Metab. 99 (10): 3543–50. doi:10.1210/jc.2014-2262. PMC 5393495. PMID 25279572.
- Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N (2017). "Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis". Fertil. Steril. 107 (2): 475–482.e15. doi:10.1016/j.fertnstert.2016.10.028. PMID 27916205.
- Cappelletti M, Wallen K (February 2016). "Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens". Horm Behav. 78: 178–93. doi:10.1016/j.yhbeh.2015.11.003. PMC 4720522. PMID 26589379.
- Reed BG, Bou Nemer L, Carr BR (2016). "Has testosterone passed the test in premenopausal women with low libido? A systematic review". Int J Women's Health. 8: 599–607. doi:10.2147/IJWH.S116212. PMC 5066846. PMID 27785108.
- Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR (March 2016). "Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction". J Sex Med. 13 (3): 305–16. doi:10.1016/j.jsxm.2015.11.015. PMID 26944462.
- Stone L (November 2017). "Sexual medicine: Transdermal oestrogen is effective". Nat Rev Urol. 14 (11): 638. doi:10.1038/nrurol.2017.152. PMID 28895561.
- Pal L, Sayegh RA (January 21, 2017). Essentials of Menopause Management: A Case-Based Approach. Springer. pp. 180–. ISBN 978-3-319-42451-4.
- Lobo RA, Kelsey J, Marcus R (May 22, 2000). Menopause: Biology and Pathobiology. Academic Press. pp. 454–. ISBN 978-0-08-053620-0.
- Bagatell C, Bremner WJ (May 27, 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 374–. ISBN 978-1-59259-388-0.
- L'Hermite M (June 2017). "Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use". Climacteric. 20 (3): 205–211. doi:10.1080/13697137.2017.1285277. PMID 28509626.
- Nieschlag E, Behre HM (December 6, 2012). Testosterone: Action - Deficiency - Substitution. Springer Science & Business Media. pp. 1–, 9, 298, 309–331, 349–353, 366–367. ISBN 978-3-642-72185-4.
- Melmed S (January 1, 2016). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 760–769. ISBN 978-0-323-29738-7.
- Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 385–394, 413, 426, 607, 666. ISBN 978-0-9828280-1-4.
- Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. pp. 18–19, 331, 336. ISBN 978-0-12-137250-7.
- "S1. Anabolic Agents | List of Prohibited Substances and Methods". English. Archived from the original on May 27, 2016. Retrieved June 6, 2016.
- "Anabolic Steroid Control Act" (PDF). United States Sentencing Commission. 1990. Archived from the original (PDF) on August 30, 2016. Retrieved November 11, 2016.
- Karkazis K, Jordan-Young R (April 11, 2014). "The Trouble With Too Much T". New York Times. Archived from the original on April 12, 2014. Retrieved April 12, 2014.
- Fagan K (August 13, 2016). "Katie Ledecky is crushing records, so why are we still worried about Caster Semenya?". ESPN. Archived from the original on August 18, 2016. Retrieved August 27, 2016.
- Padawer R (June 28, 2016). "The Humiliating Practice of Sex-Testing Female Athletes". The New York Times. ISSN 0362-4331. Archived from the original on June 28, 2016. Retrieved August 27, 2016.
- Strahm E, Emery C, Saugy M, Dvorak J, Saudan C (December 2009). "Detection of testosterone administration based on the carbon isotope ratio profiling of endogenous steroids: international reference populations of professional soccer players". British Journal of Sports Medicine. 43 (13): 1041–44. doi:10.1136/bjsm.2009.058669. PMC 2784500. PMID 19549614.
- Kicman AT, Cowan DA (January 2009). "Subject-based profiling for the detection of testosterone administration in sport". Drug Testing and Analysis. 1 (1): 22–4. doi:10.1002/dta.14. PMID 20355155.
- Pozo OJ, Deventer K, Van Eenoo P, Rubens R, Delbeke FT (August 2009). "Quantification of testosterone undecanoate in human hair by liquid chromatography-tandem mass spectrometry". Biomedical Chromatography. 23 (8): 873–80. doi:10.1002/bmc.1199. PMID 19353724.
- Baselt RC (2008). Disposition of Toxic Drugs & Chemicals in Man (8th ed.). Foster City, Calif: Biomedical Publications. pp. 1501–04. ISBN 978-0-9626523-7-0.
- Kavoussi P, Costabile RA, Salonia A (October 19, 2012). Clinical Urologic Endocrinology: Principles for Men's Health. Springer Science & Business Media. pp. 65–. ISBN 978-1-4471-4405-2.
- Perry MC (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 368–. ISBN 978-0-7817-7328-7. Archived from the original on September 8, 2017.
- Grech A, Breck J, Heidelbaugh J (October 2014). "Adverse effects of testosterone replacement therapy: an update on the evidence and controversy". Therapeutic Advances in Drug Safety. 5 (5): 190–200. doi:10.1177/2042098614548680. PMC 4212439. PMID 25360240.
- "Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility". Lancet. 336 (8721): 955–9. October 1990. doi:10.1016/0140-6736(90)92416-F. PMID 1977002.
- Rhoden EL, Morgentaler A (February 2004). "Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole". International Journal of Impotence Research. 16 (1): 95–7. doi:10.1038/sj.ijir.3901154. PMID 14963480.
- Yates, William R. (2000). "Testosterone in Psychiatry". Archives of General Psychiatry. 57 (2): 155. doi:10.1001/archpsyc.57.2.155. ISSN 0003-990X.
- Johnson JM, Nachtigall LB, Stern TA (2013). "The effect of testosterone levels on mood in men: a review". Psychosomatics. 54 (6): 509–14. doi:10.1016/j.psym.2013.06.018. PMID 24016385.
- Davidson JM, Kwan M, Greenleaf WJ (1982). "Hormonal replacement and sexuality in men". Clin Endocrinol Metab. 11 (3): 599–623. doi:10.1016/s0300-595x(82)80003-0. PMID 6814798.
- Bagatell C, Bremner WJ (May 27, 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 144, 259–261, 351. ISBN 978-1-59259-388-0.
- Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, Miles BJ, Lipshultz LI, Khera M (August 2013). "Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy". The Journal of Urology. 190 (2): 639–44. doi:10.1016/j.juro.2013.02.002. PMC 4544840. PMID 23395803.
- "Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement - Risks Associated With Abuse and Dependence". FDA. October 25, 2016. Archived from the original on October 27, 2016. Retrieved October 26, 2016.
- Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN (January 2014). "Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men" (PDF). PLOS ONE. 9 (1): e85805. Bibcode:2014PLoSO...985805F. doi:10.1371/journal.pone.0085805. PMC 3905977. PMID 24489673. Archived from the original (PDF) on March 4, 2016. Retrieved November 11, 2016.
- Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM (November 2013). "Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels". JAMA. 310 (17): 1829–36. doi:10.1001/jama.2013.280386. PMID 24193080.
- Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (July 8, 2010). "Adverse events associated with testosterone administration". The New England Journal of Medicine. 363 (2): 109–22. doi:10.1056/NEJMoa1000485. PMC 3440621. PMID 20592293.
- Staff (January 31, 2014). "FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on February 19, 2014. Retrieved September 17, 2014.
- Tavernise S (September 17, 2014). "F.D.A. Panel Backs Limits on Testosterone Drugs". New York Times. Archived from the original on September 17, 2014. Retrieved September 18, 2014.
- Staff (September 5, 2014). "FDA Panel To Review Testosterone Therapy Appropriateness and Safety". CNN News. Archived from the original on September 11, 2014. Retrieved September 14, 2014.
- Staff (September 17, 2014). "Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety And Risk Management Advisory Committee (DSARM AC) – FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT): 1. The appropriate indicated population for TRT, and 2. The potential for adverse cardiovascular outcomes associated with use of TRT" (PDF). Food and Drug Administration. Archived (PDF) from the original on September 6, 2014. Retrieved September 14, 2014.
- Staff (June 19, 2014). "FDA adding general warning to testosterone products about potential for venous blood clots". FDA. Archived from the original on October 6, 2014. Retrieved October 9, 2014.
- Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM (January 2007). "Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials". Mayo Clinic Proceedings. 82 (1): 29–39. doi:10.4065/82.1.29. PMID 17285783.
- Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM (June 2010). "Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 95 (6): 2560–75. doi:10.1210/jc.2009-2575. PMID 20525906.
- "Testosterone Products: Drug Safety Communication – FDA Investigating Risk of Cardiovascular Events". FDA. January 31, 2014. Archived from the original on February 14, 2014. Retrieved February 3, 2014.
- Rhoden EL, Averbeck MA (November 2009). "Testosterone therapy and prostate carcinoma". Current Urology Reports. 10 (6): 453–59. doi:10.1007/s11934-009-0072-1. PMID 19863857.
- Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ (August 2005). "Prostate cancer in men using testosterone supplementation". The Journal of Urology. 174 (2): 534–38, discussion 538. doi:10.1097/01.ju.0000165166.36280.60. PMID 16006887.
- Calistro Alvarado L (2010). "Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men". American Journal of Human Biology. 22 (4): 449–55. doi:10.1002/ajhb.21016. PMID 20087895.
- Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B (November 2004). "Human prostate cancer risk factors". Cancer. 101 (10 Suppl): 2371–490. doi:10.1002/cncr.20408. PMID 15495199. Lay summary – Mercer University School of Medicine.
- "Testosterone Pregnancy and Breastfeeding Warnings". Archived from the original on February 1, 2014. Retrieved February 1, 2014.
- Jameson JL, de Kretser DM, Marshall JC, De Groot LJ (May 7, 2013). Endocrinology Adult and Pediatric: Reproductive Endocrinology. Elsevier Health Sciences. pp. 1–. ISBN 978-0-323-22152-8. Archived from the original on September 8, 2017.
- Blume-Peytavi U, Whiting DA, Trüeb RM (June 26, 2008). Hair Growth and Disorders. Springer Science & Business Media. pp. 182–. ISBN 978-3-540-46911-7. Archived from the original on September 8, 2017.
- Bagatelle C, Bremner WJ (May 27, 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 78–. ISBN 978-1-59259-388-0.
- Baskin LS (December 6, 2012). Hypospadias and Genital Development. Springer Science & Business Media. pp. 37–. ISBN 978-1-4419-8995-6.
- Neurosteroids. Frontiers E-books. pp. 357–358. ISBN 978-2-88919-078-2.
- Simpson ER (September 2003). "Sources of estrogen and their importance". J. Steroid Biochem. Mol. Biol. 86 (3–5): 225–30. doi:10.1016/S0960-0760(03)00360-1. PMID 14623515.
- Nieschlag, volume editor, Eberhard Nieschlag, Hermann M. Behre, Susan; Behre, Hermann M.; Nieschlag, Susan (2009). Andrology : male reproductive health and dysfunction (3rd ed.). Berlin: Springer. p. 459. ISBN 978-3-540-78354-1.
- Wecker L, Watts S, Faingold C, Dunaway G, Crespo L (April 1, 2009). Brody's Human Pharmacology. Elsevier Health Sciences. pp. 468–469. ISBN 978-0-323-07575-6.
- Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1116, 1119, 1152, 1182–1185, 1195–1197, 2146. ISBN 978-0-7817-1750-2. Archived from the original on May 5, 2017.
- Wein AJ, Kavoussi LR, Partin AW, Peters CA (October 23, 2015). Campbell-Walsh Urology. Elsevier Health Sciences. pp. 7207–. ISBN 978-0-323-26374-0.
- Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–21. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- Burtis CA, Ashwood ER, Bruns DE (October 14, 2012). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier Health Sciences. pp. 1947–. ISBN 978-1-4557-5942-2. Archived from the original on May 22, 2016.
- Kohtz AS, Frye CA (2012). Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models. Methods in Molecular Biology. 829. pp. 397–431. doi:10.1007/978-1-61779-458-2_26. ISBN 978-1-61779-457-5. PMID 22231829.
- Nieschlag E, Behre HM, Nieschlag S (January 13, 2010). Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. pp. 49–54, 441–446. ISBN 978-3-540-78355-8. Archived from the original on June 23, 2016.
- Strauss JF, Barbieri RL, Gargiulo AR (December 23, 2017). Yen & Jaffe's Reproductive Endocrinology E-Book: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. pp. 292–. ISBN 978-0-323-58232-2.
- Behre, Hermann M.; Nieschlag, Eberhard; Nieschlag, Eberhard; Behre, Hermann M.; Nieschlag, Susan (July 26, 2012). "Testosterone preparations for clinical use in males". In Eberhard Nieschlag; Hermann M. Behre; Susan Nieschlag (eds.). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 309–335. doi:10.1017/CBO9781139003353.016. ISBN 978-1-107-01290-5.
- Elks J (November 14, 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–642. ISBN 978-1-4757-2085-3. Archived from the original on February 15, 2017.
- Jameson JL, De Groot LJ (February 25, 2015). Endocrinology: Adult and Pediatric. Elsevier Health Sciences. pp. 2387–. ISBN 978-0-323-32195-2.
- Chapple CR, Steers WD (May 10, 2011). Practical Urology: Essential Principles and Practice: Essential Principles and Practice. Springer Science & Business Media. pp. 228–. ISBN 978-1-84882-034-0.
- Gregory HG, Travis TN (September 23, 2015). Essentials of Strength Training and Conditioning 4th Edition. Human Kinetics. pp. 229, 233. ISBN 978-1-4925-0162-6.
- Taylor WN (January 16, 2002). Anabolic Steroids and the Athlete (2nd ed.). McFarland. pp. 180–. ISBN 978-0-7864-1128-3.
- Hoberman J (February 21, 2005). Testosterone Dreams: Rejuvenation, Aphrodisia, Doping. University of California Press. pp. 134–. ISBN 978-0-520-93978-3.
- Mundy AR, Fitzpatrick J, Neal DE, George NJ (July 26, 2010). The Scientific Basis of Urology. CRC Press. pp. 294–. ISBN 978-1-84184-749-8.
- Adis R&D Profile (2004). "Testosterone Undecanoate—Schering AG". Drugs. 5 (6): 368–369. doi:10.2165/00126839-200405060-00012. PMID 15563244.
- Nieschlag, Eberhard; Nieschlag, Susan (2017). "The History of Testosterone and The Testes: From Antiquity to Modern Times". Testosterone. pp. 1–19. doi:10.1007/978-3-319-46086-4_1. ISBN 978-3-319-46084-0.
- Nieschlag, Eberhard; Nieschlag, Susan (2019). "ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use". European Journal of Endocrinology. 180 (6): R201–R212. doi:10.1530/EJE-19-0071. ISSN 0804-4643. PMID 30959485.
- Nieschlag, Eberhard; Nieschlag, Susan (2014). "Testosterone deficiency: a historical perspective". Asian Journal of Andrology. 16 (2): 161–8. doi:10.4103/1008-682X.122358. ISSN 1008-682X. PMC 3955324. PMID 24435052.
- Morgentaler, Abraham; Traish, Abdulmaged (2018). "The History of Testosterone and the Evolution of its Therapeutic Potential". Sexual Medicine Reviews. 8: 286–296. doi:10.1016/j.sxmr.2018.03.002. ISSN 2050-0521. PMID 29661690.
- "Male Menopause". www.nhs.uk. NHS Choices. April 8, 2016. Archived from the original on October 9, 2016. Retrieved October 7, 2016.
- Gorski D (November 25, 2013). ""Low T": The triumph of marketing over science « Science-Based Medicine". Science-Based Medicine. Archived from the original on September 11, 2016.
- Perls T, Handelsman DJ (April 2015). "Disease mongering of age-associated declines in testosterone and growth hormone levels". Journal of the American Geriatrics Society. 63 (4): 809–11. doi:10.1111/jgs.13391. PMID 25809947.
- "Testosterone - International - Drugs.com". Drugs.com. Archived from the original on November 13, 2016. Retrieved November 12, 2016.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN 978-3-88763-075-1.
- Владимир Мюллер (April 15, 2016). Англо-русский словарь. Русско-английский словарь. 250 000 слов. ЛитРес. pp. 643–. ISBN 978-5-457-98308-3.
- "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on November 16, 2016. Retrieved November 16, 2016.
- Morley JE, van den Berg L (November 5, 1999). Endocrinology of Aging. Disease-A-Month : Dm. 34. Springer Science & Business Media. pp. 141–. doi:10.1016/s0011-5029(98)90024-4. ISBN 978-1-59259-715-4. PMID 3044718.
- Bagatell C, Bremner WJ (May 27, 2003). Androgens in Health and Disease. Springer Science & Business Media. ISBN 978-1-59259-388-0.
- "Drug Product Database - Health Canada". Health Canada. March 18, 2010. Archived from the original on November 19, 2016. Retrieved November 13, 2016.
- Karch SB (December 21, 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN 978-1-4200-0346-8.
- Lilley LL, Snyder JS, Collins SR (August 5, 2016). Pharmacology for Canadian Health Care Practice. Elsevier Health Sciences. pp. 50–. ISBN 978-1-77172-066-3.
- Harris A. "Abbott Labs Sued by Five Men Claiming Androgel Injuries". Bloomberg.com. Bloomberg, L.P. Archived from the original on July 14, 2014. Retrieved June 16, 2014.
- Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT (February 2014). "Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials". Annals of Clinical Psychiatry. 26 (1): 19–32. PMID 24501728.[permanent dead link]
- Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M (July 2009). "Testosterone and depression: systematic review and meta-analysis". J Psychiatr Pract. 15 (4): 289–305. doi:10.1097/01.pra.0000358315.88931.fc. PMID 19625884.
- Wang W, Jiang T, Li C, Chen J, Cao K, Qi LW, Li P, Zhu W, Zhu B, Chen Y (May 2016). "Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials". Journal of Thoracic Disease. 8 (5): E269–77. doi:10.21037/jtd.2016.03.39. PMC 4842839. PMID 27162680.
- Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA (May 2012). "Testosterone Supplementation in Heart Failure: A Meta-Analysis". Circulation: Heart Failure. 5 (3): 315–21. doi:10.1161/CIRCHEARTFAILURE.111.965632. PMID 22511747.
- Wang C, Festin MP, Swerdloff RS (2016). "Male Hormonal Contraception: Where Are We Now?". Current Obstetrics and Gynecology Reports. 5: 38–47. doi:10.1007/s13669-016-0140-8. PMC 4762912. PMID 26949570.
- Chao JH, Page ST (July 2016). "The current state of male hormonal contraception". Pharmacology & Therapeutics. 163: 109–17. doi:10.1016/j.pharmthera.2016.03.012. PMID 27016468.
- "Testosterone intranasal (low-dose)". Archived from the original on September 6, 2017. Retrieved September 5, 2017.
- Traish AM, Saad F, Guay A (2009). "The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance". Journal of Andrology. 30 (1): 23–32. doi:10.2164/jandrol.108.005751. PMID 18772488.
- Pike CJ, Rosario ER, Nguyen TV (April 2006). "Androgens, aging, and Alzheimer's disease". Endocrine. 29 (2): 233–41. doi:10.1385/ENDO:29:2:233. PMID 16785599.
- Rosario ER, Chang L, Stanczyk FZ, Pike CJ (September 2004). "Age-related testosterone depletion and the development of Alzheimer disease". JAMA. 292 (12): 1431–32. doi:10.1001/jama.292.12.1431-b. PMID 15383512.
- Gruber CJ, Wieser F, Gruber IM, Ferlitsch K, Gruber DM, Huber JC (December 2002). "Current concepts in aesthetic endocrinology". Gynecol. Endocrinol. 16 (6): 431–41. doi:10.1080/gye.16.6.431.441. PMID 12626029.
- Nieschlag E, Behre HM, Nieschlag S (January 13, 2010). Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. ISBN 978-3-540-78355-8.
- Nieschlag E, Behre HM, Nieschlag S (July 26, 2012). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. ISBN 978-1-107-01290-5.
- Hohl A (March 30, 2017). Testosterone: From Basic to Clinical Aspects. Springer. ISBN 978-3-319-46086-4.
- Nieschlag E, Nieschlag S (2014). "Testosterone deficiency: a historical perspective". Asian J. Androl. 16 (2): 161–8. doi:10.4103/1008-682X.122358. PMC 3955324. PMID 24435052.
- Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. ISBN 978-0-9828280-1-4.
- Shoskes JJ, Wilson MK, Spinner ML (December 2016). "Pharmacology of testosterone replacement therapy preparations". Transl Androl Urol. 5 (6): 834–843. doi:10.21037/tau.2016.07.10. PMC 5182226. PMID 28078214.